GENB (Generate Biomedicines) Total Stockholders Equity: $-615.97 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GENB Generate Biomedicines Inc GENB
6 GF Score
Price $15.63
! 1 Warning Sign
View Full Analysis

What is Generate Biomedicines Total Stockholders Equity?

Generate Biomedicines GENB +4.48% 6 Total Stockholders Equity is $-615.97 Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

Generate Biomedicines's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-615.97 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Generate Biomedicines's Book Value per Share for the quarter that ended in Dec. 2025 was $-4.83. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Generate Biomedicines's Debt-to-Equity for the quarter that ended in Dec. 2025 was -0.11.

Generate Biomedicines  (NAS:GENB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Generate Biomedicines's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-615.965-0)/127.450
=-4.83

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Generate Biomedicines's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(15.008 + 53.518) / -615.965
=-0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Total Stockholders Equity Related Terms

Generate Biomedicines Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Total Stockholders Equity Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Total Stockholders Equity
-434.52 -615.97

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Total Stockholders Equity -434.52 -615.97
GENB
6GF Score
Generate Biomedicines Inc GENB
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-615.97 Mil mean?
Generate Biomedicines (GENB) has a Total Stockholders Equity of $-615.97 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Generate Biomedicines and its competitors.
Is Generate Biomedicines' Total Stockholders Equity too high?
Generate Biomedicines' current Total Stockholders Equity is $-615.97 Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Total Stockholders Equity compare to ZYME and DMRA?
Generate Biomedicines' Total Stockholders Equity of $-615.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Generate Biomedicines and its competitors. Generate Biomedicines's current Total Stockholders Equity is $-615.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Total Stockholders Equity of $-615.97 Mil. The current Total Stockholders Equity is $-615.97 Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Total Stockholders Equity is $-615.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.63
Price